JP2019500334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500334A5 JP2019500334A5 JP2018527863A JP2018527863A JP2019500334A5 JP 2019500334 A5 JP2019500334 A5 JP 2019500334A5 JP 2018527863 A JP2018527863 A JP 2018527863A JP 2018527863 A JP2018527863 A JP 2018527863A JP 2019500334 A5 JP2019500334 A5 JP 2019500334A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- aso
- cancer
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 26
- 239000000074 antisense oligonucleotide Substances 0.000 claims 25
- 238000012230 antisense oligonucleotides Methods 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- TWGNOYAGHYUFFR-UHFFFAOYSA-N 5-methylpyrimidine Chemical group CC1=CN=CN=C1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 claims 2
- LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 claims 2
- 108091027075 5S-rRNA precursor Proteins 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260837P | 2015-11-30 | 2015-11-30 | |
| US62/260,837 | 2015-11-30 | ||
| PCT/CA2016/000296 WO2017091885A1 (en) | 2015-11-30 | 2016-11-30 | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500334A JP2019500334A (ja) | 2019-01-10 |
| JP2019500334A5 true JP2019500334A5 (enExample) | 2019-12-26 |
| JP7039470B2 JP7039470B2 (ja) | 2022-03-22 |
Family
ID=58795956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527863A Active JP7039470B2 (ja) | 2015-11-30 | 2016-11-30 | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10889814B2 (enExample) |
| EP (1) | EP3384028B1 (enExample) |
| JP (1) | JP7039470B2 (enExample) |
| CN (1) | CN108603194A (enExample) |
| AU (1) | AU2016363683B2 (enExample) |
| CA (1) | CA3006827A1 (enExample) |
| ES (1) | ES2893294T3 (enExample) |
| MX (1) | MX2018006527A (enExample) |
| WO (1) | WO2017091885A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
| MX2019001389A (es) | 2019-01-31 | 2020-02-20 | Atso Corp Affairs S A De C V | Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer. |
| EP3999117A4 (en) * | 2019-07-12 | 2023-07-26 | Duke University | NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF |
| CN113197903B (zh) * | 2021-05-08 | 2022-01-07 | 江南大学 | 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用 |
| WO2022250466A1 (ko) * | 2021-05-27 | 2022-12-01 | 사회복지법인 삼성생명공익재단 | 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물 |
| CN113717971B (zh) * | 2021-08-10 | 2025-03-28 | 南通大学 | PGK1靶向siRNA干扰库及其应用 |
| CN114324870A (zh) * | 2021-12-22 | 2022-04-12 | 中国人民解放军空军军医大学 | 靶向髓系细胞乳酸转运信号的肺癌生物标志物和检测试剂盒 |
| CN114246829B (zh) * | 2021-12-31 | 2023-03-24 | 北京大学 | 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832763A1 (de) | 1997-07-21 | 1999-03-18 | Schuster Christoph | Kraftfahrzeug mit einem verschließbaren Fahrerraum |
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US20030059781A1 (en) * | 2000-03-21 | 2003-03-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer |
| US6637473B2 (en) | 2000-10-30 | 2003-10-28 | Robodesign International, Inc. | Automated storage and retrieval device and method |
| NZ538841A (en) | 2002-10-02 | 2006-10-27 | Univ British Columbia | Compositions for reducing hsp27 for the treatment of prostate and other cancers |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20050255114A1 (en) * | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| GB2407837B (en) | 2003-11-04 | 2007-07-11 | Corus Uk Ltd | Traffic control barriers |
| US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| WO2017091885A1 (en) | 2015-11-30 | 2017-06-08 | The University Of British Columbia | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer |
-
2016
- 2016-11-30 WO PCT/CA2016/000296 patent/WO2017091885A1/en not_active Ceased
- 2016-11-30 MX MX2018006527A patent/MX2018006527A/es unknown
- 2016-11-30 US US15/779,419 patent/US10889814B2/en active Active
- 2016-11-30 EP EP16869430.5A patent/EP3384028B1/en active Active
- 2016-11-30 CA CA3006827A patent/CA3006827A1/en active Pending
- 2016-11-30 CN CN201680069706.0A patent/CN108603194A/zh active Pending
- 2016-11-30 ES ES16869430T patent/ES2893294T3/es active Active
- 2016-11-30 AU AU2016363683A patent/AU2016363683B2/en active Active
- 2016-11-30 JP JP2018527863A patent/JP7039470B2/ja active Active
-
2020
- 2020-11-16 US US17/099,516 patent/US11466273B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bian et al. | Emerging delivery systems for enabling precision nucleic acid therapeutics | |
| Ashrafizadeh et al. | Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer | |
| J O'Loughlin et al. | Exosomes and the emerging field of exosome-based gene therapy | |
| Tyagi et al. | Exploiting nanotechnology for the development of microRNA-based cancer therapeutics | |
| Love et al. | Not miR-ly small RNAs: big potential for microRNAs in therapy | |
| JP2020040969A5 (enExample) | ||
| JP2018512060A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JP2012505250A5 (enExample) | ||
| CN109563509A (zh) | 靶向长非编码rna的减小尺寸的自递送核酸化合物 | |
| Miller | Delivery of RNAi therapeutics: work in progress | |
| AU2014359716A1 (en) | Means for lung specific delivery | |
| CN102712928A (zh) | 反义抗病毒化合物及治疗流感病毒感染的方法 | |
| JP2014054250A5 (enExample) | ||
| JP6484223B2 (ja) | バクテリオファージ | |
| Guo et al. | Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? | |
| JP2020533411A5 (enExample) | ||
| JP2021533825A5 (enExample) | ||
| Sarli et al. | Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo | |
| Koli et al. | SiRNA-based therapies for pulmonary diseases | |
| Hyodo et al. | “Programmed packaging” for gene delivery | |
| AU2017205650A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| Li et al. | Lipid-based vehicles for siRNA delivery in biomedical field | |
| Wang et al. | mRNA therapy for myocardial infarction: A review of targets and delivery vehicles | |
| WO2014124155A2 (en) | Methods for inducing cardiomyocyte proliferation |